These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7545499)

  • 81. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.
    Musa AM; Noazin S; Khalil EA; Modabber F
    Trans R Soc Trop Med Hyg; 2010 Jan; 104(1):1-2. PubMed ID: 19712953
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients.
    Alimohammadian MH; Kivanjah M; Pak F; Gaznavia A; Kharazmi A
    Trans R Soc Trop Med Hyg; 1993; 87(5):550-1. PubMed ID: 8266406
    [No Abstract]   [Full Text] [Related]  

  • 83. [Serological study of Leishmania (the present-day status of the problem)].
    Saf'ianova VM
    Med Parazitol (Mosk); 1979; 48(5):54-61. PubMed ID: 94149
    [No Abstract]   [Full Text] [Related]  

  • 84. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis.
    Convit J; Castellanos PL; Ulrich M; Castés M; Rondón A; Pinardi ME; Rodríquez N; Bloom BR; Formica S; Valecillos L
    J Infect Dis; 1989 Jul; 160(1):104-15. PubMed ID: 2659679
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Blastogenic responses of peripheral blood leukocytes from owl monkeys experimentally infected with Leishmania braziliensis panamensis.
    Lujan R; Dennis VA; Chapman WL; Hanson WL
    Am J Trop Med Hyg; 1986 Nov; 35(6):1103-9. PubMed ID: 3789265
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects.
    Barral A; Costa JM; Bittencourt AL; Barral-Netto M; Carvalho EM
    Int J Dermatol; 1995 Jul; 34(7):474-9. PubMed ID: 7591410
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy.
    Ulrich M; Rodriguez V; Centeno M; Convit J
    Clin Exp Immunol; 1995 Apr; 100(1):54-8. PubMed ID: 7697923
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis.
    Christensen SM; Belew AT; El-Sayed NM; Tafuri WL; Silveira FT; Mosser DM
    PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007152. PubMed ID: 30845223
    [TBL] [Abstract][Full Text] [Related]  

  • 89. IFN-gamma and delayed-type hypersensitivity are associated with cutaneous leishmaniasis in vervet monkeys following secondary rechallenge with Leishmania major.
    Olobo JO; Reid GD; Githure JI; Anjili CO
    Scand J Immunol Suppl; 1992; 11():48-52. PubMed ID: 1514049
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Development of a storable Leishmania tropica vaccine: field testing with frozen promastigotes.
    Witztum E; Greenblatt CL; Kark J; Spira DT; Koufman Z; Michaeli D
    Isr J Med Sci; 1979 Sep; 15(9):749-53. PubMed ID: 511513
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Delayed-type hypersensitivity and immunoglobulin E in American cutaneous leishmaniasis.
    Lynch NR; Yarzábal L; Verde O; Avila JL; Monzon H; Convit J
    Infect Immun; 1982 Dec; 38(3):877-81. PubMed ID: 7152676
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy.
    Castes M; Moros Z; Martinez A; Trujillo D; Castellanos PL; Rondon AJ; Convit J
    Parasite Immunol; 1989 May; 11(3):211-22. PubMed ID: 2671867
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies.
    Brito RC; Guimarães FG; Velloso JP; Corrêa-Oliveira R; Ruiz JC; Reis AB; Resende DM
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208616
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immunological aspects of clinical leishmaniasis.
    Bryceson AD
    Proc R Soc Med; 1970 Oct; 63(10):1056-60. PubMed ID: 4249442
    [No Abstract]   [Full Text] [Related]  

  • 95. Non-parasite-specific cytokine responses may influence disease outcome following infection.
    Akuffo HO
    Immunol Rev; 1992 Jun; 127():51-68. PubMed ID: 1506007
    [No Abstract]   [Full Text] [Related]  

  • 96. [Determination of antibodies by immunofluorescence in sera of patients with recent cutaneous lesions of mucocutaneous American leishmaniasis].
    Chiari Cde A; Magalhães P; Mayrink W
    Rev Inst Med Trop Sao Paulo; 1973; 15(5):304-9. PubMed ID: 4596819
    [No Abstract]   [Full Text] [Related]  

  • 97. Further trials of a vaccine against American cutaneous leishmaniasis.
    Mayrink W; Antunes CM; Da Costa CA; Melo MN; Dias M; Michalick MS; Magalhães PA; De Oliveira Lima A; Williams P
    Trans R Soc Trop Med Hyg; 1986; 80(6):1001. PubMed ID: 3299899
    [No Abstract]   [Full Text] [Related]  

  • 98. Leishmania aethiopica: experimental infections in non-human primates.
    Hailu A; Negesse Y; Abraham I
    Acta Trop; 1995 Jun; 59(3):243-50. PubMed ID: 7572430
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immune responses during cutaneous and visceral leishmaniasis.
    Kedzierski L; Evans KJ
    Parasitology; 2014 Jul; ():1-19. PubMed ID: 25075460
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Applying the indirect immunofluorescency test to the study of American cutaneous leishmaniasis.
    Convit J; Pinardi ME
    Dermatol Int; 1969; 8(1):17-20. PubMed ID: 4898831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.